The phase III multinational, randomized, double-blind study evaluated trifluridine and tipiracil plus best supportive care (BSC) versus placebo plus BSC in patients with metastatic gastric cancer refractory to standard treatments.
The median OS in patients treated with trifluridine/tipiracil was 5.7 months as compared to 3.6 months when treated with placebo, and they had a 31% risk reduction of death. At 12-months, OS rates were 21.2% in the trifluridine/tipiracil group and 13.0% in the placebo group. In addition, the risk for disease progression measured by progression free survival was reduced by 43%.
Servier, governed by a non-profit foundation, has an international presence in 148 countries and employs 21,000 people worldwide. Entirely independent, the group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development in five areas: cardiovascular, immune-inflammatory, neuropsychiatric, cancers, and diabetes.
With multiple international facilities, Taiho Pharma, focuses on developing medications and treatments for oncology, allergy and immunology, and urology.
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary